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Hepatitis C, Quality of Life and Cognitive Function: An Exploratory Study 
Active chronic hepatitis C (CHC) is a viral infection that affects approximately 
150,000 Austra1ians. It has various quality of life impacts and the literature suggests 
some CO!,'llitive ramifications. In this Western Australian exploratory study, 13 
healthy students from Edith Cowan University made up a control group. One 
experimental group consisted of 11 people with CHC and mild liver damage, and a 
second experimental group consisted of 8 people with CHC and at least moderate 
liver damage. The participants were assessed with a health-related quality ofl:ife 
questionnaire, the Short Fonn 36 Health Survey (SF-36); a test of cognitive 
functioning, the PSE-Syndrome-Test (PSE-Test); and a test of pre-morbid 
intelligence, the Nu:tional Adult Reading Test(NART). One of the aims of the study 
was to consider the local suitability of these instruments. The control grcup results 
on the SF-36 and the NART were as expected compared to relevant nonns. The 
PSE-Test, which has not been used in Australia, perfonncd as expected with one 
possible difficulty, probably relating to the translation of the instructions from 
Gennan to Australian. While the tests perfonned satisfactorily, one of the main 
conclusi,·ms of the study was that cross-sectional survey designs are problematic for 
research in this area, because of the large number of uncontrollable variables. It is 
suggeste.:l that repeated measures designs are more likely to produce credible results. 
Due to th" exploratory nature oft he study, the small number of participants and the 
lack of control over variables, it Yw'as difficult to provide convincing statistics. 
Nevertheless, the SF-36 results largely followed the pattern established in the 
literature that points to a diagnosis ofHCV as being the most important detenninant 
of health-related quality of life in people infected with the virus. The PSE-Test 
results, as adjusted by NART covariation, showed no evidence of dysfunction in the 
cognitive domains of attention, concentration and fine motor control. Indeed, the 
group with CHC and mild liver damage perfonned marginally better than the 
university students. The practical conclusion from this research, and related studies, 
is that anti-viral treabnent should be aimed at the re-establishment of current health-
related quality of life, in addition to targeting the presetvation of future quality of 
life. 
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Hepatitis C, Quality of Life and Co!,rnitive Function: 
An Exploratory Study 
Approximately 3% of the world's population, or 170 million peul'.!C, are 
infected by the hepatitis C virus (HCV; Crofts, 2001 ). Many of these people have 
hepatitis C-related reductions in quality of life (Bonkovsky & Woolley, 1999; Foster, 
Goldin, & Thoma~ 1998; Miller, Hiller, & Shaw, 2001; Rodger, Jolly, Thompson, 
Lanigan, & Crofts, 1999). Many also complain of depression, mental clouding and a 
general inability to function properly (Forton, Taylor-Robinson, & Thomas, 2003) 
and research has provided some evidence of cognitive changes in hepatitis C-
positive people (Forton, Thomas et al., 2002; Hilsabeck, Perry, & Hassanein, 2002; 
Kramer et al., 2002; Quero, Hartmann, Meulstee, Hop, & Schalm, 1996). Some 
researchers have noted a relationship between changes in quality of life and changes 
in cognitive function (Groeneweg et al., 1998). This is not surprising because 
"Cognitive function refers to those mental processes that are crucial for the conduct 
of the activities of daily living. Such mental processes include attention, short-term 
(working) memory, long-tenn memory, reasoning, the coordination of movement 
and the planning of tasks" (Wesnes, 2002, p.30). 
The current exploratory study considered the practicality of researching the 
quality of life and cognitive function ofHCV-positive people by using a cross-
sectional survey design and three instruments, one which has not been used in 
Australia and one which has not been widely used in Western Australia. This area of 
research is important because hepatitis C can have a significant impact on well-being 
and ~;an also result in various insults to the brain. As a consequence, the hepatitis C 
epidemic provides an excellent opportunity for psychologists to consider certain 
aspects of brain function and various quality of life issues. There are also 
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ramifications for the care cmd treatment of people with HCV. The following 
introduction will provide a brief overview of hepatitis C and the progression of the 
infection. The HCV-related literature on quality oflife and. cognitive functioning will 
then be reviewed 
A full-scale study published by COrdoba et al. in August 2003, covered 
similar ground to this present study. In one sense this detracts from the exploratory 
nature of the current study, however, as there are diffei-ences in geography and 
instruments used, greater breadth has been added to the area of research. 
Hepatitis C Epidemiology 
Infection with HCV is a leading cause of liver disease, cirrhosis, liver failure, 
hepatocellular carcinoma (HCC) and it is also the most common reason for liver 
transplantation in Australia (Farrell & Cossart, 1999), The Hepatitis C Virus 
Projections Working Group (2002) estimated that approximately 1%, or about 
150,000 Australians, have active HCV and that the incidence of new infections in 
2001 >_;-;<as 16,000. It is however important to recognise that HCV statistics are 
particularly problematic, especially the incidence figures, because the infection is 
often asymptomatic especially in the early stages. Also, HCV is a relatively recently 
reccgnised health problem and notifications do not reliably distinguish new 
infections from the delayed reporting of old infections (Atthowe, Thompson, & 
Giele, 2003; Staff, Bmabic, Schwarz, & Holt, 2000). 
HVC is one of six viral hepatides: A, B, C, D, E, and G (Howard, 2002). 
Hepatitis A and hepatitis B were isolated in the early 1970s, but it was soon 
recognised that another viral infection was also causing liver damage. This became 
known as ·non-A, non-B hepatitis' until it was properly identified in 1989 (Choo et 
al., 1989). Tests for antibodies to HCV were available in 1989 but these tests, while 
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cheap, resulted in false positives for the approximately 25% of people who 
spontaneously clear the virus and false negatives, because it takes four to six months 
from the time of infection for antibodies to be detectable (Bowden, 2001). In 1990 
the polymerase chain reaction (PCR) technique was developed to detect active HCV 
and according to Bowden the PCR assay is the most common1y used assay for the 
detection of active HCV in Australia. 
Hoofnagle (2002) noted that active HCV has a nbonucleic acid (RNA) 
genome, which provides the coding for the replication of the virus. This takes place 
in the cytoplasm ofliver cells where the virus does not directly cause liver cell death. 
In Hoofhagle's view, liver cell damage is caused by rapid virus replication and 
continuous cell-to-cell spread. The coding sequence ofHCV genomes can differ 
significantly and six major genotypes with more than 50 sub-types have been 
described. Hoofnagle suggested that the different HCV genotypes are similar in 
clinical expression with the most important exception being their different responses 
to interferon treatment. 
Crofts (2001) provided an interesting and descriptive history ofHCV, going 
back hundreds of years, and noting wide geographic variations in HCV prevalence, 
different genotype distributions and different modes of transmission. In Australia, 
Crofts estimated that genotype I accounts for 50 to 60% of all prevalent infection, 
genotype 2 about 10%, while genotype 3a accounts for 30 to 40%. However, 
genotype 3a is increasing relative to the other genotypes because it is more recent 
and is common amongst intravenous drug users. Crofts also pointed out that 
genotype 4 from North Africa and the Middle East and genotype 6, from South-East 
Asia, are being more frequently found in Australia due to migration and international 
travel. 
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Transmission ofHCV is almost entirely, if not always, by blood to blood 
contact, with percutaneous exposures, such as transfusions with infected blood 
products, shared drug injection equipment and needle-stick injuries, being the most 
efficient means of transmitting the virus (MacDonald & Wodak, 1999). The 
Hepatitis C Virus Projections Working Group (2002) concluded that of those 
currently living with the virus in Australia, 83% were infected due to unsafe 
injecting, 5% due to the infected blood supply prior to 1990, and 12% due to other 
causes such as unsterile body piercing, needle stick injuries, unsterile medical 
procedures, and transmission from mother to child which may occur in about 2 to 
5% of births to mothers with detectable HCV-RNA (Atthowe et al., 2003). It is 
important to note that HCV is not transmitted through hugging, kissing, cooking 
utensils, sneezing, coughing, toilets, or drinking glas,ses and it is only transmitted 
sexually when there is blood-to-biood contact (Atthowe et al. ). 
Treatment of Hepatitis C 
No consideration ofHCV should ignore the great progress that has been 
made with treatments since the virus was isolated in 1989. There are good prospects 
of a cure for the majority of infected people and this should condition all thinking 
about HCV. In the early 1990s limited ~mccess was had with the use of interferon 
(IFN) administered subcutaneously three times per week for 12 months. However, 
Dore (200 I) noted that only about 10 to 20% of patients were HCV -negative as 
tested by PCR, six months after the end of treatment (a sustained viral response or 
SVR). By the late 1990s treatment with combination therapy (IFN and ribavirin) 
resulted in 30% of patients with genotype 1 achieving SVR after 12 months 
treatment, while patients with genotypes 2 and 3a achieved a 65% success rate after 
six months treatment (Sievert, 200 l ). Recent research has concentrated on tibavirin 
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and IFN with the large polyethylene glycol molecule (Cheng, 2003). Use of this 
pegylated interferon requires an injection only once per week as it has a slow release 
that maintains a steady level of IFN in the body. Studies with pegylated interferon 
and ribavirin suggest that SVR can be expected in approximately 50% of those with 
genotype I after 48 weeks of treatment, and 80% of those with genotype 2 and 3a, 
after 24 weeks of treatment (Cheng; Fried et al., 2002; Matms et al., 2001 ). 
Pegylated interferon is the best treatment available in the United States and many 
Australians are holding off alternative treatments until pegylated interferon has heen 
approved for use in Australia. Cheng expects approval by late 2003. 
Progression of Hepatitis C to Fibrosis/Cirrhosis 
Once a person is infected with HCV there is a rapid onset of the acute phase 
of the infection with HCV-RNA almost always being detectable by PCR within one 
to two weeks (Hoofnagle, 2002). Liver damage is indicated by an increased release 
into the blood stream of the enzymes alinane aminotransferase (ALT) and aspartate 
aminotransferase (AST). Hoofnagle noted that increases in ALT and AST levels in 
the blood start to rise two to eight weeks after exposure to HCV and symptoms such 
as malaise, weakness, anorexia and jaundice occur at this stage in approximately one 
third of infections. The symptoms, if any, last for three to four weeks after which 
they decline along withAL T and AST levels. In about 25% of cases HCV infection 
resolves itself (Alter et al., 1999) and Hoofnagle pointed to some evidence 
suggesting that spontaneous resolution occurs more frequently in young people, 
women, and ironically, in people whose acute symptoms are more severe. If 
resolution of the infection is not achieved within six months then the infection is 
taken to be chronic and the spontaneous resolution of chronic hepatitis C (CHC) is 
unusual (Yokosuka et al., 1999). 
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Once chronic infection has set in, the major issue is fibrosis and its potential 
progression to cirrhosis and end-stage liver disease, or hepatocellular carcinoma 
(I-ICC). Fibrosis is the result of a sustained wounding/healing process that initially 
causes inflammation of the liver. If the process continues, scarring may bring about 
changes to liver architecture and the deterioration of liver functions that include 
blood detoxification, glucose storage, the synthesis of bile precursors, and the 
manufacture of blood coagulation factors and neurotransmitter precursors (Tarter, 
Edwards, & Van Thiel, 1988). 
For people with HCV it is important to assess the degree ofliver damage. 
Some idea can be gained by ALT and AST levels in the blood, but these serum 
markers fail to discriminate accurately between different fibrosis stages. At present 
the only reliable way to assess liver damage is by sampling the liver with a biopsy 
(Friedman, 2003). Histological examination results in the staging of the fibrosis, by 
using the Metavir score (four stages), or the modified Knodell system (Ishak et al., 
1995). The seven stages of the Knodell system ranging from 0 (no fibrosis) through 
varying degrees of structural liver damage to stage 6 (cirrhosis) are detailed in 
Appendix A. In this thesis <mild chronic HCV' will include Knodell stages 0 to 2. 
The tenn covers inflammation of the liver tracts, but no partial blocking or bridging 
of the tracts. 'Moderate chronic HCV' will include Knodell stages 3 to 5 which is to 
the point when there is marked bridging or partial blocking of the tracts. Knodel1 
stage 6 fibrosis (cirrhosis) includes the fonnation of nodules that block the liver 
tracts and impedes blood flow in the liver. 
It is impossible to generalise about the rate of progression of fibrosis and many 
studies have been done on different populations and by using different research 
designs. In an effort to bring meaning to this area of research Freeman et al. (200 I) 
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analysed 57 studies which were divided into: a) cross-sectional studies of people 
referred to liver clinics; b) longitudinal studi~s of people with post-transfusion HCV; 
c) cross-sectional surveys of persons newly diagnosed at blood donor centres; and d) 
longitudinal community-based research such as studies of people followed up after 
proven acute infection. Freeman et al. (2001) found in their review, that estimates of 
progression to cirrhosis after 20 years from infection was 22% in the liver clinic 
studies, 24% in the post-transfusion studies, 4% for the blood donors and 7% in the 
community-based studies. These findings are consistent with both Poynard et at. 
(200 I), who estimated that on average 9% of those with CHC become cirrhotic in 20 
years from infection and 44% in 40 years, and also Alberti and BenvegnU (2003) 
who concluded that about 20% of those with CHC progress to cirrhosis (Knodell 
stage 6). Freeman eta!. (2001) also confinned the research ofPoynard et al. (2001) 
in finding that three factors were associated with faster fibrosis progression; older 
age at time of infection, alcohol consumption of SOg or more per day and male 
gender. 
One of the concerns of some HCV research is the single categorisation of 
cirrhotics. In clinical practice in Australia it is common to distinguish between three 
groups of cirrhotics by using the Child-Pugh classification (W. D. Reed, personal 
communication, May, 2003). The classification relics on assessing: a) overt 
cognitive impainnent which is almost certainly caused, in part, by the inability of the 
liver to clear toxins from the blood; b) abnonnal fluid levels in the peritoneal cavity 
(ascites) due mainly to the obstruction of portal vein blood flow through the 
damaged liver; c) excessive bile in the blood Gaundice) which is caused by the 
inability of the damaged liver to process the bile appropriately; d) inadequate 
manufacture, by the liver, of albumin causing oedema; and e) increased bleeding-
----------------------------........ 
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time due to the liver's failure to manufacture clotting agents (Pugh, Murray-Lyon, 
Dawson, Pietroni, & Williams, 1973). 
When the patient is cirrhotic (Knode II stage 6), but the assessment of functions 
by the Child-Pugh classification is favourable, then the patient is considered t1.; have 
compensated cirrhosis and is classified as Child-Pugh A. However, when the 
assessment is unfavourable the patient is considered to have decompensated cirrhosis 
and the classification will almost certainly be Child-Pugh B/C. In patients with 
decompensated cirrhosis, episodes of ascites, jaundice, cognitive impainnent or 
gastrointestinal bleeding can be expected to start and Fattovich et al. (1997) found 
that after the first decompensation episode the probability of survival for 5 years was 
50%. 
Friedman (2003) estimated that 40% of Child-Pugh A cirrhotics are 
asymptomatic and therefore they are probably outside the health system. Studies 
with consecutive cirrhotic patients attending outpatient clinics indicate that about 
75% of patients under health care are Child-Pugh A (Groeneweg et a!., 1998; Quero, 
et at., 1996; Romero-GOmez, Boza, Garcia-Valdecasas, Garcia, & Aguilar-Reina., 
2001). Thus, about 25% of the 60% of cirrhotics receiving medical attention, or 15% 
of all cirrhotics, are Child-Pugh B/C. The Hepatitis C Virus Projections Working 
Party (2002) has published similar, but not identical figures (Table I; p.l5). 
In swnmary, the progression of hepatitis C can be divided into the following 
broad phases; the acute phase, and if the infection does not spontaneously resolve 
itself the infected person will move to the CHC phase, firstly with mild chronic HCV 
(Knode II stages 0 to 2),· possibly progressing to moderate chronic HCV (Knode II 
stages 3 to 5) and then possibly to Child-Pugh A cirrhosis and finally to Child-Pugh 
B/C cirrhosis. Putting numbers to this progression can only be done as a gross 
Hepatitis C and Quality of Life 9 
generalisation, but such generalisations give some idea of magnitude. Of say, 100 
jX"ople who become infected with HCV, 25 of them will spontaneously clear the 
virus and 75 will progress to CHC. Of this 75, about 15 will progress to ChildMPugh 
A cirrhosis over a variable, but extended period of time, perhaps as long as 40 years. 
Of the approximately 15 people who progress to ChildMPugh A cirrhosis, and again 
over an extended period of time, perhaps two people will progress to Child-Pugh 
B/C cirrhosis. In the meantime, less than one person will develop hepatocellular 
carcinoma (HCC). 
HCV and Health-Related Quality of Life (HRQOL) 
Quality of life is concerned with general wellbeing, health, activity level, social 
support, personal resources, accomplishments and spirituality (Koff, 1999). 
However, in health care settings Koffnoted that a more narrowly defined health-
related quality of life (HRQOL) has been increasingly used in medical decision-
making and research. With the patient being the focal point, a good HRQOL means 
good physical and emotional functionality and wellbeing. As Koff and Owens (1998) 
have pointed out, HRQOL encapsulates, and in a sense summarises, all the physicaJ 
and mental symptoms being experienced by an individual. Thus, measurements of 
HRQOL can be used to consider and compare different health conditions and the 
outcomes of medical mterventions.Forton, Thomas, Taylor-Robinson (2003) noted 
that the usual quantitative measure of health status for HCV research is the Short 
Fonn 36 Health Survey (SF-36; Ware, Snow, & Kosinski, 2000). This instrument 
provides scales for eight health dimensions: physical functioning, role physical, 
bodily pain, general health, vitality, social functioning, role emotional, and mental 
health, and swnmruy scores for physical and mental components. 
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It is almost impossible to consider HRQOL in the approximately 58,000 
Australians with CHC who have not been diagnosed (Hepatitis C Virus Projections 
Working Group, 2002). There is some limited evidence that these people may have 
small decrements in HRQOL (Dunne & Quayle, 2001; Rodger et al., 1999). 
However, it is not until HCV has been diagnosed that participants can be recruited 
for larger scale studies. Such studies have convincingly shown that an HCV -positive 
diagnosis is a significant determinant of reduced HRQOL. 
Possibly the best of these studies (Koff, 1999), was by Bonkovsky and 
Woolley (1999). They recruited 358 Child-Pugh A cirrhotir.s and 284 non-cirrhotic 
people from the United States and Canada. HRQOL instruments included the SF-36. 
The questionnaires were self administe1 ed by the participants at baseline and after 24 
weeks of interferon monotherapy, but before participants found out whether or not 
they had cleared the virus. The baseline results were compared with 750 healthy 
controls who had significantly higher (better) scores (p < .001) on all eight scales of 
the SFM36. This crossMsectional analysis with such numbers is important research, but 
Bonkovsky and Woolley also used an even more convincing repeated measures 
analysis for one aspect of the study. They waited six months after treatment to 
detennine which patients had a sustained HCV-negative response (SVR). The results 
for these SVRs were analysed and there were statistically significant SF-36 
differences from the healthy controls at baseline. However, these differences were 
reduced to below the level of significance by the end of treatment, except on one 
scale, general health. The decrement ofHRQOL at baseline, plus the marked 
improvement after successful treatment, for the SVRs, provided convincing support 
for the hypothesis that those people diagnosed with hepatitis C have a significant 
deteriomtion in HRQOL and that this improves with the eradication of the virus. 
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The Bonkovsky and Woolley (1999) research leaves the remote, but logical 
possibility, that the HCVMpositive participants had significantly reduced HRQOL 
prior to diagnosis. However, the Australian study by Rodger et al. ( 1999) specifically 
underscores the potency of an unfavourable diagnosis. The researchers used stored 
frozen serum from 238 patients who were diagnosed with acute viral hepatitis 
between 1971 and 1975 at the Fairfield Infectious Diseases Clinic in Melbourne. By 
1999 some of these people had been located and assessed by a variety of instruments 
including the SF-36. Candidates were excluded if they were not HCVMpositive, had 
cirrhosis, had any overt clinical symptom of liver disease, or had medical conditions 
other than HCV. After the exclusions, 34 participants remained; 19 were not aware 
that they were HCV-positive prior to SF-36 testing, and 15 knew of their HCV 
status. The participants who were aware of their HCV-positive status before testing, 
scored significantly worse, on all eight scales of the SF-36 than the participants who 
were unaware of their HCV-positive status, even after adjustments were made for 
age, sex, marital status and AL Ts. This study of two well-matched groups 
convincingly showed that people who are aware of an HCV -positive diagnosis 
perceive their functionality and well-being to be less than people who have been 
HCV-positive for the same period of time, but who are not aware oftheirHCV 
status. 
It is in fact unremarkable that a diagnosis of HCV results in an immediate 
reduction in HRQOL. Qualitative research has clearly shown that such a diagnosis 
brings with it feelings of uncertainty, fear of death, tmnsmission concerns, 
depression, worry about cognitive changes, discrimination concerns, a reduction in 
roles because of fatigue and also relationship problems (Dunne & Quayle, 2001; 
Glacken, Kernahan, & Coates, 2001; Hepworth & Krug, 1999). Such qualitative 
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work is supported by a number of quantitative studies. Fatigue and emotiona1 stress, 
particularly depression, are the major symptoms reported in such studies. Lee, Jamal, 
Regenstein, and Perrillo (1997) found that 45% of their 500 CHC participants related 
a history of chronic fatigue and 24% of the untreated participants had depression. 
Fontana et al. (2002) concluded that 35% of their CHC participants had clinically 
significant emotional distress compared to an expected frequency of I 0%, while 
Gifford, O'Brien, Bammer, Banwell, and Stoove (2003) in Australia, reported that 
58% of 462 women reported symptoms relating to HCV, mainly tiredness and 
nausea. Another Australian study, McDonald, Jayasuriya, Bindley, Gonsalvez, and 
Gluseska (2002) found that approximately 50% of the 76 men and 39 women had 
significant levels of depression, anxiety, somatization, interpersonaJ sensitivity and 
hostility. The authors concluded that there was a strong correlation between fatigue 
and psychopathology, but not between fatigue and disease activity. However, they 
stopped short of concluding that fatigue was caused by psychopathology rather than 
disease severity. Wessely and Pariante (2002) on the other hand, reviewed the 
literature and concluded that there w-...s no evidence of an association between HCV-
infection per se and fatigue or depression. 
After the HRQOL decrements associated with a positive HCV diagnosis, the 
literature suggests that HRQOL does not change much even when the HCV 
progression extends to early cirrhosis. In the previously cited study by Bonkovsky 
and Woolley (1999) the 358 Child-Pugh A cirrhotics and the 284 non-cirrhotic 
participants were compared at baseline and the non-cirrhotic patients had SF-36 
scores that were only slightly better and of a similar pattern to the cirrhotics. Similar 
findings have been reported by Miller et al. (2001). They administered the SF-36 to 
95 untreated CHC patients attending two South Australian day clinics. It was found 
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that SF-36 scores did not differ significantly according to ALT levels. Foster ct aJ. 
(1998) <rlso obtained similar results in a comparison of a mild liver disease group 
(Knodell stage 2 and less) and those with moderate liver disease (Knodell stage 3 to. 
5). Results on five of the SF-36 scales were in the direction of a lesser HRQOL for 
the moderate liver damage group, but the differences did not approach statistical 
significance. 
Once Child-Pugh A cirrhosis is reached there is some evidence to suggest that 
a small proportion of people suffer HRQOL decrements because of deteriorating 
cognitive function. In a study by Groeneweg et al. (1998) 136 Child-Pugh A 
cirrhotics and 43 Child-Pugh B/C cirrhotics completed the Sickness Impact Profile 
(SIP; Bergner, Bobbitt, Cartner, & Gilson, 1981). This 136 item HRQOL 
questionnaire assesses 12 areas of daily functioning; social interaction, alertness 
behaviour, emotional behaviour, communication, ambulation, mobility, body care, 
sleep and rest, work, home management, recreation and pastimes, and eating. The 
participants in the Groeneweg et al. research were also given the Number 
Connection Test Part A (Conn, 1977), the Digit Symbol Test (Wechsler, 1955) and 
an electroencephalogram (EEG). If one or more of these tests were abnonnal then 
cognitive impainnent was diagnosed. Of the 136 Child-Pugh A cirrhotics, 25 ( 18%) 
were diagnosed with cognitive impairment and of the 43 Child-Pugh 8/C cirrhotics, 
23 (53%) were cognitively impaired. The 48 who were diagnosed with impainnent 
reported significant reductions on all 12 scales of the SIP compared with the group 
without impairment. 
In swnmary, there is possibly a small reduction in HRQOL for those with 
undiagnosed HCV and if there is, then presumably this is due to an as yet 
unidentified biological mechanism. A larger decrement occurs after diagnosis when 
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psychosocial factors become relevant. There is little change in HRQOL between 
people with mild chronic HCV and those with moderate chronic HCV. There is 
possibly some further decrement in people with Child-Pugh A cirrhosis, although 
this decrement may only be experienced by the few Child-Pugh A cirrhotics who 
experience cognitive dysfunction. Once the liver disease progresses to Child-Pugh 
B/C there is a very considerable reduction in HRQOL because such people will have, 
or will shortly have, the serious consequences of decompensation, such as overt 
cognitiYe dysfunction, jaundice, gastrointestinal bleeding and ascites. 
This pattern ofHRQOL decrements has been quantified in Australia by the 
Hepatitis C Virus Projections Working Group (2002). They estimated HRQOL 
adjustments in order to calcuJate quality of life years lost due to HCV infection. The 
HRQOL adjustments in Table I are taken from Table 9 of the Working Group's 
Report, (p. 25). The HRQOL adjushnents were largely derived from a panel of 
hepatologists (Bennett et al., 1997). The adjustments are somewhat smaller than 
suggested by patients in a study comparing judgements by hepatologists and patients 
(Cotler et al., 200 I). Nevertheless, they reflect a consensus pattern that has been 
recently reaffinned by COrd~Jba et al. (2003}. These researchers recruited four groups 
of 40 participaots. Each group had a different HCV status: good health, mild HCV, 
Child-Pugh A cirrhosis, or Child-Pugh B/C cirrhosis. The only difference between 
COrdoba et al. (2003) and the estimates of the Hepatitis C Virus Projections Working 
Group (2002). was that the latter authors showed a significant reduction ofHRQOL 
for Child-Pugh A cirrhotics compared to those with moderate HCV. C6rdoba et al. 
(2003) did not find this decrement. 
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Table I 
Estimated HRQOL AdJustments due to HCV Infection- Australia 
HCV infection progression Knodel! 
Fibrosis Stage 
Mild Chronic HCV- Undiagnosed 0-2 
Mild Chronic HCV - Diagnosed 0-2 
Moderate Chronic HCV - 3-5 Undiagnosed 
Moderate Chronic HCV- Diagnosed 3-5 
Compensated Cirrhosis- Undiagnosed 6 (A)b 
Compensated Cirrhosis- Diagnosed 6(A)b 
Decompensated Cirrhosis - Diagnosed 6 (B/C)b 
Note. 
Estimated 
Persons 
2001 
50,000 
74,000 
7,000 
20,000 
1,000 
4,100 
1,300 
HRQOL 
Adjustmentsa 
6% 
18% 
6% 
18% 
16% 
26% 
68% 
8The adjustment, or discount, required to enable comparisons of quality of life years 
between HCV-positive and healthy persons. bChild-Pugh classification in brackets. 
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HCV-Related Liver Disease and Cognitive Function 
It has been well established that clinically overt cognitive dysfunction is 
sometimes found in people with a non-~ctional (decompensated) liver and one of 
the main causes of decompensation is CHC (Mullen & Dasarathy, 1999). This 
clinically obst:rvable dysfunction will be called overt hepatic encephalopathy ( oHE). 
Detailed in Appendix B are the different types of oHE and the nomenclature 
recommended in the Final Report of the Working Party at the 11th World Congresses 
of Gastroenterology, Vienna 1998 (Ferenci et al., 2002). This Working Party stated 
that oHE is a neuropsychiatric disorder that involves " ... cognitive, 
affective/emotiona.\ behavioural, and bio-regulatory domains. Different traits can be 
defined within each domain. For example, cognition may include evaluation of 
psychomotor speed, visuopraxis, attention, concentration, abstracting, and a level of 
consciousness" (p. 718). 
The oHE syndrome is normally graded in severity from I to 4 by the West 
Haven Criteria (Appendix C; Ferenci et al., 2002). These authors also noted that the 
most common type of oHE: episodic hepatic encephalopathy, is coded as ·oelirium 
Due to a General Medical Condition (Code 293.0)' in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM IV; American Psychiatric Association, 1994). 
Other DSM·IV codings are discussed in detail by Wiltfang, Nolte, Weissenborn, 
Kornhuber, and Ruther ( 1998). 
The pathogenesis of hepatic enceph~lopathy has not yet been fully 
determined, but what is definitely implicated, is the action of gut-derived ammonia 
and other neuro·toxins that have not been metabolised by the badly damaged liver 
(Butterworth, 2002; Haussinger, Schliess, & Kircheis, 2002). The neuro-toxins pass 
through the blood brain barrier and almost certainly cause swelling in Alzheimer 
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type 11 astrocytes, particularly in the basal ganglia (Weissenborn & Kolbe, 1998). 
Weissenborn and Kolbe suggested that the swelling of these astrocytes causes 
disturbances in neurotrans!llission that in turn results in changes to sleep patterns, 
behavioural disinhibition, psychomotor slowing, loss of intellectual flexibility,loss 
of concentration, and neuro-muscular symptoms including the inability to co-
ordinate muscle activity (ataxia), clumsy hand syndrome (dysarthria), and 
involuntary motor movements ~specially in the hands (asterixis). These symptoms 
are similar to many of those exhibited in other subcortical dementias such as 
Parkinson's dementia and Huntington's chorea (Brown & Marsden, 1998; Middleton 
& Strick, 2000; Turner, Moran, & Kopelman, 2002). An interesting review of 17 
patients with oHE was provided by Summerskill, Davidson, Sherlock, and Steiner 
(1956) and a precis is in Appendix D. 
The oHE syndrome has been considered in some detail largely because it 
provides a picture of where the syndrome's precursor, minimal hepatic 
encephalopathy (mHE) is heading (Romero-Gomez et al., 2001). This early phase of 
hepatic encephalopathy was first recognised by Zeegen, Drinkwater, and Dawson 
(1970) who found cognitive impairment in cirrhotic patients who did not have oHE 
(Conn, 1994). The disorder was then usually called 'sub-clinical hepatic 
encephalopathy' but Ferenci et al. (2002) recommended the term 'minimal hepatic 
encephalopa~y' largely to remove the implication that the disorder had no clinical 
significance. After a number of studies confirming the existence of mHE a definition 
was given by Gitlin (1988). This is still used today (Das, Dhiman, Saraswat, Verma, 
& Naik, 2001). Gitlin's definition was "a condition in which patients with cirrhosis, 
regardless of its etiology, demonstrate a number of quantifiable neuropsychological 
Hepatitis C and Quality of Life 18 
defects, yet they have a normal mental and neurological status to clinical 
examination"(p. 8). 
The(e has been much variation in the reported prevalence of mHE in cirrhotics. 
Also, many authors appear to extrapolate to all cirrhotics, the results obtained from 
studies of Child-Pugh B/C cirrhotics. Consequently, mHE prevalence figures of up 
to 80% of aU cirrhotics have been implied (Kircheis, Wettstein, Timmermann, 
Schnitzler, & Ha.ussinger, 2002). Few researchers have clearly studied mHE in 
different Child-Pugh classifications, but Quero et al. (1996) estimated that 14% of 
Child-Pugh A cirrhotics and 45% of Child-Pugh B/C cirrhotics had mHE. However, 
Das et al. (2001) concluded that the prevalence of mHE was 56% in Child-Pugh A, 
65% in Child-Pugh B, and 64% in Child-Pugh C. As is the case with nearly ali work 
on mHE, it is almost impossible to comment on such varying estimates as different 
methodologies, different patient groups and different tests for assessing mHE have 
been used (Weissenborn, 2002). However, the issue is important because the 
Hepatitis C Virus Projections Working Group (2002) estimated, for 2001, that 6,400 
Australians had cirrhosis, but of these only 1300 had Child-Pugh B/C cirrhosis. 
Using the prevalence figures from Quero et al. about 700 Australians with Child-
Pugh A cirrhosis might have mHE. In contrast the Das et al. figures would suggest 
that there would be about 2,800 with mHE. 
While there may be differing conclusions about the prevalence and 
distribution of mHE, there is consensus that mHE definitely does exist, but this 
consensus only relates to cirrhotic people. However, a recent study by Hilsabeck et 
al. (2002) suggested that pre-cirrhotic HCV-positive people might have mHE. This 
study was concerned with some of the questions being considered by the current 
research. A quotation from the introduction is of interest 
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In patients with cirrhosis and end-stage liver disease, 
newopsychological impairment has been well documented .... in 
patients with HCV infection, it often takes more than 20 years of 
chronic hepatic injury before the liver develops cirrhosis and its 
complications. During this time, liver function is impaired, albeit 
slightly. The possibility that cognitive dysfunction may result from 
slight impairment of liver fimction, even before the development of 
cirrhosis, has not been well examined, .... (p. 440). 
Hilsabeck et al. (2002) took a random sample of 269 people from patients 
attending an outpatient clinic at the University of California. After significant 
attrition and exclusions, the researchers were left with three groups; hepatitis C only 
(n = 44)~ hepatitis C plus another chronic illness (n = 22) and a group with non-
HCV-related liver disease (n = 14). These participants were also split between non-
cirrhotic (n = 40) and cirrhotic people (n = 34). The authors concluded, among other 
things, that a significant percentage of non-cirrhotic patients had cognitive deficits in 
the domains of attention, concentration, visual scanning, psychomotor speed and 
mental flexibility, as measwed by the Digit Cancellation Test (Franklin, Heaton, 
Nelson, Filley, & Seibert, 1988), the Trail Making Tests A & B (Reitan & Wolfson, 
1993), and the Symbol Digit Modalities Test (Smith, 1982). No deficits were found 
in the non-cirrhotic patients in the domains of memory and visuoconstructional 
abilities as measwed by a modified version of the Rey Complex Figwe Test 
(Franklin et al. ). In addition the researchers found no significant cognitive 
differences between the 'hepatitis C only group' and the 'non-HCV liver damage 
group' which emphasised liver damage per se as the determinant of cognitive 
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dysfunction and detracted from a recent suggestion th~t the HCV virus directly 
attacks the central nervous system. 
The Hepatitis C Virus and the Central Nervous System (CNS) 
To recap, there can be no doubt that a liver seriously compromised by HCV-
related damage cm, _,se encephalopathy. The issue of importance regarding 
encephalopathy is how much liver damage is necessary to cause mHE? Up until the 
research by Hilsabeck et al. (2002) there was consensus that liver damage had to be 
at least to the stage of Child-Pugh A cirrhosis. The article by Hilsabeck eta!. has 
raised a concern that mHE may extend backwards in the progression ofHCV to 
people with moderate chronic HCV. 
Recently however, an even more pervasive threat has been raised. It has been 
suggested by Forton, Thomas et at. (2002) that people with HCV may be exposed to 
an encephalopathy caused by a direct viral attack on the nervous system (HCV 
encephalopathy-HCVE). In their research 27 HCV-positive people aod !6 HCV-
cleared people were given, among other tests, the National Adult Reading Test 
(NART; Nelson & Willison, !991), the Number Connection Tests A & B (NCT A & 
B; Conn, !977) and the Digit Symbol Test (Wechsler, !955). Both groups had a high 
proportion of professional and skilled participants and the mean NART IQ 
equivalent scores were 117 for the HVC-positive group and 115 for the HVC-cleared 
group. The authors did not detail the results for the paper and pencil tests but noted, 
"there were no statistically significant differences between the study groups on any 
of the paper-based tasks" (p. 435). Wesnes (2002) suggested that the reason for there 
being no deficits was because the paper and pencil tests were not sufficiently 
sensitive. 
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For this reason the two groups in the Forton, Thomas et al. (2002) study also 
completed the Cognitive Drug Research Computerised Assessment Battery (CDR-
Batu:ry; Kennedy, Scholey, Tildesley, Peny, & Wesnes, 2002). This battery has 
been used in the psychopharmacology field in repeated measures studies to test the 
cognitive effects of drugs and herbs (Kennedy, Scholey, & Wesnes, 2002; Kennedy 
Scholey, Tildeslcy et al., 2002; McKeith et al, 2000; Siegfried, 1993). The battery 
uses desktop computer presentations to assess four domains: speed of attention 
(reaction times and digit vigilance), accuracy of attention (accuracy on digit 
vigilance and choice reaction times), quality of memory (word, picture, number, and 
spatial memory-immediate and delayed recall), and speed of memory (time taken on 
memory tasks). The HCV -positive group in the study scored significantly worse than 
the HCV -cleared group on two factors, speed of attention and speed of memory 
processes, and in a subsequent review Forton, Taylor-Robinson, and Thomas (2003) 
further described these deficits as being "selective impairments of attention, 
concentration and psychomotor speed" (p. 83). 
Forton, Thomas et al. (2002) also took a subset of 17 of the HCV-positive 
participants and found that they had proton magnetic resonance spectroscopy results 
showing metabolite abnormalities in the basal ganglia. These neurophysiological 
findings were supported by Kramer et al. (2002). They studied 100 HCV-positive 
people by using PJOO event-related brain potentials (Weissenborn et al., 1990). 
Seventeen of the participants ha:.l prolonged P300 latencies that reportedly correlate 
with information processing speed, and reaction time. The authors concluded that 
people with HCV could have a slight but significant neurocognitive impairment that 
was not related to stage of infection, severity of fatigue, or mental health impairment. 
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A third group of authors (Krause et al., 2001) has also suggested CNS 
involvement in HCV infection. These authors studied 30 HCV -positive people with 
nonnal AL Ts and ASTs and found that half the participants suffered from chrorllc 
fatigue as measured by the Fatigue Impact Scale (PIS; Fisk et al., 1994). They then 
found that these fatigued HCV-positive pmticipants performed poorly on attention 
and memory tests, not specified in the short poster session report. The conclusion 
that HCV causes CNS involvement, which then causes fatigue, is clearly at odds 
with the previously cited review by Wessely and Pariante (2002). 
HCVE, if it exists, is clearly a syndrome awaiting d~;tinition,just as minimal 
hepatic encepha1opathy was 33 years ago. Much work has to be done to define the 
characteristics ofHCVE because at present only one behavioural test and two 
physiological tests have been used to define the disorder. The behavioural test; the 
CDR Battery appears not to be well known or included in reference works such as 
Lezak (1995) or Spreen and Strauss (1998). The neurophysiological tests, as far as is 
known, do not have well documented behavioural correlates. By contrast, mHE has 
been much studied and its neuropsychological characterisation is available for 
examination. 
Neuropsychological Characterisation ofmHE 
The first attempt to characterise mHE utilised the Trail Making Tests (1MT). 
These were used by Zeegen et al. (1970) who concluded that a combined time of 130 
seconds on 1MT A and B distinguished between cirrhotics with and witlwut mHE, 
given the exclusion by clinical examination of cirrhotics with oHE. Conn (1977) 
reported that he used the TMT tests, but found that practise effects distorted results 
when the tests were administered serially to the same person. Consequently, Conn 
modified the TMT and constructed four different, but equivalent versions and called 
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them the Number Connection Tests (NCT). By the early 1990s Conn (1994) noted 
that either the TMT or NCT had been used in nearly all studies ofmHE since 1970. 
In reviewing the mHE literature Conn (1994) not only found that the TMf and 
NCT were widely used, he also found that a large nwnber of other instruments were 
used. He made the point that the sheer diversity of data made it impossible to analyse 
and compare studies. An increasing realisation of this problem led to the presentation 
of three papers at the Ninth International Symposiwn on Ammonia in 1996. These 
papers aimed at clarifying the neuropsychological dimensions of mHE and they all 
presented studies in which participants with cirrhosis completed comprehensive test 
programmes. From these test programmes shorter batteries were developed with a 
high sensitivity and specificity to mHE (COrdoba, McCrea, Vessey, Blei, & 
Randolph, 1997; Watanabe et al., 1997; Weissenborn et al., 1997). By 1999the work 
presented by Weissenborn et al. (1997) culminated in the publication in Gennany of 
thePSE-Syndrome-Test (PSE-Test; Schomerus, Weissenborn, Hamster, RUckert, & 
Hecker, 1999). This test was subsequently recommended for use in mHE research by 
a consensus group of international experts formed at the 11th World Congresses of 
Gastroenterology, 1998 (Ferenci et at., 2002). 
Describing the PSE-Test Weissenborn, Ennen, Schomerus. RUckert, and 
Hecker et al. (200 1) wrote that it "examines motor speed and accuracy, visual 
perception, visuo-spatial orientation, visual construction, concentration, attention and 
to a lesser extent, memory. None of the tests is a true classical test of attention 
However, a successful performance of all tests requires an unimpaired attention 
ability" (p. 771 ). This characterisation of mHE followed closely LeW<' s 1995 
description of the cognitive aspects of subcortical dementia " ... cognitive dysfunction 
typically appearing as slowed mental processing, disturbances of attention and 
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concentration, executive disabilities including impaired ability to manipulate 
concepts or to generate strategies, visuospatial abnormalities, and a memory disorder 
that primarily affects retrieval rather than learning" (p. 221 ). The correspondence of 
these two passages is not surprising because of the implication of the basal ganglia in 
the pathogeneses of mHE as previously discussed. 
The PSE-Test clearly does not attempt to directly assess the complex and 
subtle emotional changes of subcortical dementias which are seen mainly as apathy 
and depression (Lezak, 1995). Nevertheless, these mood-states do contribute to test 
performance through the mediation of motivation and attention. The question of 
whether the PSE-Test is a good test of attention and concerrtration was the subject of 
a paper by Weissenborn, Heidenreich, Ennen, RUckert, and Hecker {200 1 ). In this 
study people with poor PSE-Test results also did badly on a wide range of well-
recognised attention tests. In a recent article Weissenborn, Heidenreich, 
Giewekemeyer, RUckert, and Hecker (2003) addressed the. relationship between the 
PSE-Test and the traditional memory tests. Weissenborn et al. concluded that people 
with mHE do perform poorly on some memory tasks, but largely because of deficits 
in attention and visual perception. The emphasis on motor deficits in the PSE-Test is 
consistent with Lezak's conclusion that such deficits are the first indicators of 
subcortical disorders. 
There are five paper and pencil sub-tests in th.:: PSE-Test and the best known is 
the Digit Symbol Test (DST; Wechsler, 1981). The PSE version oftheDST is 
almost identical to theW AIS-R sub-test. In the DST symbols are related to nwnbers 
and the coding rules are established at the top of the page. ·The participant is asked to 
code the correct symbols into rows of numbered boxes. The test score is the number 
of symbols coded correctly in 90 seconds. Lezak (1995) noted that the DST is the 
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most sensitive to brain dmnage of any of the Wechsler tests, that it is extremely 
sens;tive to dementia, being one of the final WAIS-R tests to decline, and it is a1so 
one of the few Wechsler tests on which Huntington patients perform poorly before 
overt manifestations of the disease. Wechsler noted that the Digit Symbol Test's 
correlation with the WAIS-R full-scale score is r ==.57. 
NCT A andNCT Bare also included in the PS&Test. TheseTMT type tests 
are simple tests that take between five and ten minutes to administer (Spreen & 
Strauss, 1998). The TMT-A and NCT-A ('A' tests) require the participant to draw a 
line as quickly as possible to consecutively join the numbers 1 to 25. The test result 
is the time needed to perfonn the task. The skills required are visuospatial scanning, 
motor speed, alertness, some planning ability, and good motivation (Lezak, 1995; 
Spreen & Strauss, 1998). The TMT-B and NCT-B ('B' tests) require the participant, 
as quickly as possible, to connect numbers (I to 13) and letters (A to L) in an 
alternating sequence (l, A, 2, B,. _. L, 13. ). The 'B' tests require the same skiiJs as the 
'A' tests, but there are additional higher skills needed because it is necessary to hold 
two sets ofinfonnation and switch between them (Conigan & HinkedJey, 1987). 
As well as being used to assess brain damage (Reitan, 1958) the TMT type 
tests have been used to assess chemical insults and drug abuse (Hartman, 1995), mild 
head trawna (Mathias & Coats, 1999), and certain types of medically induced brain 
injury (Fanner, 1994). The TMT tests are widely used in Australia and only four 
other instruments are used more frequently by neuropsychologists (Sullivan & 
Bowden, 1997). 
When the PSE-Test was being developed in the mid-1990s the test programme 
that was used by Schomerus and Hamster (1998) tested similar skills to the 
programmes used by C6rdoba et al. (1997) and Watanabe et al. (1997), but they also 
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drew on Edwin A. Fleishman's work in isolating separate psychomotor skills 
(Fleishman, 1954; Fleishn~ln & Ellison, 1962). Schomerus and Hamster found two 
psychomotor factors in particu1ar that helped to discriminate between healthy 
controls and people with mHE. These were, firstly the motor speed and coordination 
as required by the ability to 'dot' or 'tap' with rapid repetitive movements of the 
fingers and wrist, and secondly the motor speed and steadiness of ann and hand 
required for peg board tasks and drawing accurately between two lines. Schomerus 
and Hamster then modified some of the Fleishman tasks to test for these factors. The 
two paper and pencil tests were ca11ed Serial Dotting and Line Tracing. The Serial 
Dotting Test asks the participant to place a dot inside each of 100 circles as quickly 
as possible. The Line Tracing Test requires the participant to draw a continuous line 
between two parallel lines in a maze-like pattern. The participant needs to go as fast 
as possible without touching or crossing the parallel lines. These two psychomotor 
tests were included in the PSE-Test along with the NCT A, NCT B and the DST. 
The PSE-Test has been derived from 30 years of work to characterise mHE. It 
has been recommended for use in studies of mHE by most of the leaders in the field 
of hepatic encephalopathy (Ferenci et al., 2002) and it should be used with a high 
degree of confidence. It also includes sub-tests that are widely used to assess 
generalised brain function. 
Research Questions 
This was an exploratory study and it was important to consider whether the 
instruments used perfonned satisfactorily in the Western Australian environment and 
whether the study design was satisfactory. 
Regarding substantive HCV issues, this research was aimed at enhancing 
knowledge about the following hypotheses: a) HRQOL decreases when a diagnosis 
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ofHCV infection is received; b) subsequent to the decrement associated with 
diagnosis, HRQOL remains constant until liver damage causes overt failures of liver 
functioning; c) in people with mild HCV (Knode II stages 0 to 2), changes to the 
central nervous system result in cognitive dysfunction; d) mHE is found in HCV-
positive people with moderate fibrosis (Knodell stages 3 to 5) and Child-Pugh A 
cirrhosis; and e) reduced HRQOL is associated with cognitive dysfunction. 
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Method 
Study Design 
The current study used a one-way, between-su~ject design. The independent 
variable, HCV status, had three levels: no HCV or other health problems; mild 
chronic HCV (Knndell fibrosis stages 0 to 2); and moderate chronic HCV (Knodell 
fibrosis stage 3 to Child-Pugh A cirrhosis). The dependent variables were scores on 
the SF-36 and the PSE-Test. The NART was administered as a potential covariate. 
Participants 
To form the healthy control group, contact was made with student volunteers 
on the Edith Cowan University School of Psychology Participant Research Register. 
To match as closely as possible, the expected demographics of the patient groups, 
the ten females on the Participant Research Register over the age of 40, and the 12 
males on the Register over the age of25, were targeted. From those who could be 
contacted, and reported no physical or mental health problems, 15 students agreed to 
participate and were tested. Two were excluded because of health problems that 
became apparent at the testing sessions. The final healthy control (n = 13) consisted 
of five females (mean age~ 46.40; range 43 to 50) and eight males (mean age~ 
32.00; range 24 to 42). 
The two HCV wpositive groups were recruited from the patients of a medical 
consultant at the Hollywood Private Hospital Specialist Centre. Patients were not 
considered for recruitment if there was any clinically observable cognitive 
dysfunction ( oHE), or any comorbidities that seemed likely to affect cognitive 
function. Patients were also excluded if they had English language difficulties, 
although two patients were recruited whose English was competent, but whose main 
education was in a non· English speaking country. Knodell fibrosis stage was 
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determined largely by liver biopsy although some biopsies were performed some 
years ago. 
After exclusions, a random sap1ple of patients with mild HCV were contacted 
and 11 agreed to participate. This mild HCV group consisted of six females (mean 
age~ 44.00; range 40 to 49) and five males (mean age~ 46.40; range 35 to 56). 
After exclusions, all patients with moderate HCV were contacted and eight agreed to 
participate. The moderate HCV group consisted of two females (mean age= 55.00~ 
range 42 to 68) and six males (mean age~ 49.00; range 45 to 60}. 
Instruments 
Three. instruments were used: the Short Form 36 Health Survey (SF-36~ Ware, 
Snow, & Kosinski, 2000); the PSE-Syndrome-Test (PSE-Tes~ Schomcrus, 
Weissenborn, Hamster, RUckert, & Hecker, 1999); and the National Adult Reading 
Test (NART; Nelson & Willison, 1991). 
Shorl Form 36 Heallh Survey (SF-36) 
The SF-36 is a generic measure of health status that assesses the main physical 
and mental health dimensions affected by illness, disease and treattnent. The 36 
items in the Survey were drawn from a 245-item questionnaire used in the Rand 
Medical Outcomes Study (Tarlov et at., 1989). Eight dimen'iions are assessed: 
physical functioning; role limitations due to physical health; bodily pain; social 
fWlctioning; general mental health; role limitations due to emotional problems; 
vitality energy or fatigue; and general health perceptions. The SF-36 also has two 
summary scores: physical component summary (PCS) and mental component 
summary (MCS). The Australian Bureau of Statistics (ABS, 1997) detailed the 
relationships between the eight dimensions and the Swvey's 36 items and also sets 
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out the Australian SF-36 norms derived from respondents to the 1995 National 
Health Survey. 
The SF-36 is a self-report survey and is mainly in Likert format with a small 
number of Yes/No questions. An Excel scoring format was developed to perform the 
calculations required by the Manuals: recalibrate responses as necessary, sum the 
scores for each dimension, and transform and standardise these to T -scores. These 
were additionally converted to the two component summary scores by use of factor 
weights given by the ABS. The Excel scoring format was checked by use of a data 
set provided by the SF-36 publisher, QualityMetric. 
Reliability coefficients for the instrument fall in the range of r = .70 tor= .90 
and a large range of validation strategies are reported in the Manual. The SF-36 is 
the most used behavioural measure in contemporary medicine according to Kaplan 
and Saccuzzo ( 1997) and has been used extensively in HCV research (Forton, 
Thomas, & Taylor-Robinson, 2003). 
PSE-Syndrome-Tesl (PSE-Test) 
The PSE-Test was developed as a paper and pencil test battery for the 
quantitative assessment of neuropsychological disturbances caused by liver 
dysfunction. The Manual also commends the test for the assessment of cerebral 
functions in other illnesses and pharmacological studies. It assesses fine motor 
control, attention, concentration, visuo-constructive abilities and short-term memory. 
The PSE-Test includes five sub-tests that have been considered in detail previously. 
These arc the Digit Symbol Test, the Nwnber Connection Tests A and B, Serial 
Dotting and the Line Tracing Test. 
The PSE-Test generates a composite score (CS) derived from the sub-tests. 
Results on each sub-test are compared to relevant age norms and a sub-test score is 
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awardcJ from plus one (better than one standard deviation from the mean) to minus 
three for scores worse than two standard deviations from the mean. The Line Tracing 
Test .has two results, one for time ta.lten, and one for errors made. Thus, there are six 
scores for any one participant. The scores are summed to give the CS and this has a 
possible range from plus 6 to minus 18. The normal range is plus 6 to minus 4 and 
scores worse than minus 4 are considered pathological. 
The instrument was recommended for use in studies of mHE by the consensus 
group formed at the 11th World Congresses of Gastroenterology (Ferenci et al., 
2002). Test-retest reliability coefficients quoted in the Manual are between r =.56 
and r = .95. This is a Gennan test that has not been used in Australia before. The test 
fonns were translated into English for this study. The Manual is currently being 
translated into English by Swets Test Services. 
NatioiUJI Adult Reading Test {NAII1) 
The NART assesses pre~morbid intelligence. The subject is presented with 
irregularly spelled words such as 'nai've' and is asked to read them. The scoring is 
based on correct pronunciation. Spreen and Strauss { 1998) noted reliability estimates 
of over r"" . 90 and correlations with IQ measures in the moderate to high range {r == 
.4 tor == .8). The administration followed the procedures from Beardsall and Brayne 
(1990) in that 25 words were administered first and the second 25 words were only 
administered if the participant correctly pronounced 21 or more of the first 25 words. 
Scoring also followed the Beardsall and Brayne procedures. The Borana Index was 
used to assess pre-morbid intelligence for participants who did not receive most of 
their education in English. Scoring in these cases was in accordance with the 
computational worksheet provided by Spreen and Strauss 1998 {p. 47). 
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Procedure 
Ethics approval for the study was obtained from Edith Cowan University 
Ethics Committee and the Hollywood Private Hospital Research Ethics Committee. 
Potential control group participants were contacted by telephone and patients 
were sent a letter inviting participation (Appendix E). For the people indicating a 
willingness to participate, an appoi_ntment was arranged and a confinnation letter 
(Appendix F) and Infonnation Sheet (Appendix G) were mailed, provided an address 
was available. Most of the control group were tested in a quiet office at the School of 
Psychology at Edith Cowan University, Joondalup and most of the patients were 
tested at the Hollywood Private Hospital Specialist Centre. A small number of the 
participants chose to have the tests administered at their homes, but in all cases 
testing conditions were good. 
Prior to test administration, all participants were advised of the nature of the 
study, the voluntary nature of participation, that they were allowed to withdraw at 
any time, and in the case of patients, that their participation in the study would not 
adversely affect their medical care. The Information Sheet was discussed and any 
questions were answered. An Informed Consent (Appendix H) was then completed 
and signed. When the participants were relaxed and settled the SF~36 was 
administered, followed by the PSE~Test and then the NART. After the testing 
session, time was allowed for discussion. The participants were thanked, and it was 
ensured that each participant left with a copy of the Infonnation Sheet on which were 
found various contact details. 
Scoring of the instruments was according to the manuals and statistical 
analyses were perfonned with SPSS Version 11.0 (Appendix 1). 
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Results 
Data &reening 
The accuracy of data input was confirmed by comparing data sheet totals with 
mean totals from SPSS Descriptives. Prior to analyses participants' responses on the 
SF-36, PSE-Test and the NART were examined through various SPSS programmes 
for missing values and fit between their distributions and the assumptions of 
univariate and multivariate analyses. No missing values were found and no 
univariate outliers were detected using the criterion of plus or minus 3 standard 
deviations from the mean. There were no multivariate outliers using the criterion of 
each participant having a Mahal ,·.tobis distance of less than the critical value fori at 
18df,p < .001 (42.312). 
Assessment of Instruments for Use in Western Australia 
To ensure the tests were performing satisfactorily in the Western Australian 
environment and in the hands of the researcher, comparisons of the control group's 
results were made with various norms and other studies. The use ofT-scores was 
recommended by Ware and Kosim,ki (200 1) to simplify comparisons. 
SF-36 
As shown in Table 2 the control group's results (unadjusted for age or sex) 
were slightly higher than those of a healthy Australian nonnative group. However, 
two factors bring the columns to near equivalence. The healthy Australian nonnative 
group was older and exclusions were made only for serious physical conditions 
(ABS, 1997, p. 37). The composition of the control group excluded those with 
mental as well as physical conditions. The age effect is illustrated by the differences 
shown in Table 2 between the norms for Australians aged between 35 and 44 years, 
and those between 45 and 54 years. 
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Table 2 
SF-36 Mean T-scoresafor Control Group and Australian Norms 
Healthy Healthy' Australianc Australianc 
Controls Australian Age Group Age Group 
(n = 13) (n = 9922) (n=4110) (n = 3104) 
Age (years) 37.54 44.37" 35 to 44 45 to 54 
Scale Scores 
Physical functinning 54.97 52.56 52.25 49.93 
Role physical 55.66 52.45 51.38 50.44 
Bodily pain 55.26 53.04 51.03 49.70 
General health 56.21 53.33 51.47 49.99 
Vitality 55.32 52.74 50.37 50.67 
Social functioning 54.12 52.17 50.51 50.60 
Role emotional 52.04 51.59 50.47 50.47 
Mental health 56.00 51.90 49.60 50.13 
Component Scores 
Physical 55.53 53.06 52.28 49.90 
Mental 53.89 51.66 49.42 50.57 
Note. 8 TMscore (M =50, SD =to) transfonnations have been calculated with 
norms and component score coefficients from ABS (1997, p. 31), and as 
recommended by Ware and Kosinski (2001). b ABS (p. 21). 'ABS (p. II).' 
Calculated from ABS (p. 35). 
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PSE-Test 
Table 3 shows that the PSE-Test performed as expected with the exception of 
the Line Tracing Errors sub-test. The data in this Table has not been age or sex 
adjusted and so a small advantage in favour of the control group could be ex::-~cted 
compared with the two heaJthy older groups in the Gennan stJdies. In relation to the 
Gennan nonns, the university sourced control group perfonned better, but in this 
case IQ would almost certainJy account for the differences. Thus, five sub-test scores 
were comparable with German data. 
However, for the Line Tracing Error score the control group scored 
dramatically better than the comparative groups and as can be seen from the age 
adjusted T-scores in Table 5, the study groups have done equally well on this test. 
There is clearly something different in relation to this sub-test, between the Western 
Australian study and the Gennan data. As each of the study groups have similar 
results on this sub-test, comparisons between the groups should not be affected. 
Nevertheless, the matter is currently being reviewed and details are in the 
Discussion. 
NAIIT 
The control group had a mean IQ equivalent of 116. This is at the 85th 
percentile of the general population which is an acceptable result for university 
students and comparable with the two groups of mainly skilled and professional 
people whose median scores were 117 and 115 on the NART in the study by Forton, 
Thomas et al. (2002). 
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Table3 
PSE-Syndrome-Test Mean Results for Control Gruup and German Studies 
Healthy Study' Stud/ Germane 
Controls Group Group Norms 
(n ~ 13) (n ~ 22) (n ~52) (--)' 
Mean Age (years) 37.5~ 41.00 44.40 38.00 
IQ Equivalent 1!6.00 d d 100e 
Sub Tests 
Digit Symbol 51.54 56.30 54.60 52.00 
NCTA (s) 22.31 27.30 28.10 29.00 
NCTB(s) 53.77 57.50 58.60 70.00 
Serial Dotting (s) 34.15 38.00 36.30 40.00 
Line Trac.ing Time (s) 64.54 71.90 69.30 58.00 
Line Tracing Errors 3.77 36.10 38.50 36.00 
Composite Score 2.46 1.00 1.05 0.00 
Note. "Weissenborn, Heidenreich et al. (2001). b Weissenborn et al. (2003). c 
Schomerus et al. 1999; d Not available. e Assumed. 
Hepatitis C and Quality of Life 37 
Group Comparisons 
SF-36 
Table 4 presents the SF-36 scale and component swnmary scores (PCS and 
MCS) for the three study groups. Results were transfanned toT-scores by using the 
relevant age and sex means and standard deviations provided by C. Gordon of the 
ABS (personal commlll1ication, 18 July, 2003). This age and sex adjustment was 
necessary because of the difficulty of matching the control group with HCV -positive 
groups on these variables. 
As the component scores were derived from the scale scores, only the 
component summary scores were tested for group differences. A one-way 
multivariate analysis of variance (MANOVA) was perfonned on the two dependent 
variables ofPCS and MCS. The independent variable was group (HCV status). 
Using the Pillai's Trace criterion, the combined DVs were significantly affected by 
group, F(4,58) ~ 2.74, p ~ .037. Post hoc comparisons using the Tukey HSD test 
revealed significant differences between the healthy controls and the mild HCV 
group: PCS (p ~ .036), MCS (p ~ .035). 
Because the groups were small and unequal and as the asswnption of 
homogeneity was violated for the DV ofMCS (Levene test, p < .05) the MANOV A 
results were confirmed by the non parametric Kruskal-Wallis test: PCS (p = .041) 
and MCS (p ~ .026). 
Following Bonkovsky and Woolley (1999), and for descriptive comparative 
purposes, significant Tukey post hoc results (p < .05) are asterisked in Table 4. 
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Table 4 
SF-36 Age and Sex Adjusted Mean T-scoresa for the Study Groups 
Healthy Mild Moderate 
Controls HCV HCV 
(n ~ 13) (n~ll) (n~ 8) 
Female/Male Ratio 5:8 6:5 2:6 
IQ Equivalent 116.00 111.55 100.38 
Scale Scores 
Physical functioning 53.50 50.41 48.63 
Role physical 54.65 45.04* 49.45 
Bodily pain 54.31 44.74* 49.78 
General health 54.91 39.26* 40.69* 
Vitality 54.27 43.61* 47.13 
Social functioning 53.58 45.04 49.30 
Role emotional 51.13 40.60 50.37 
Mental health 55.73 47.90 47.32 
Component Scores 
Physical (PCS) 54.10 46.48* 48.03 
Mental (MCS) 53.55 43.21* 47.81 
Note. 8 T-score (M =50, SD = 10) transformations were calculated with age and sex 
means and standard deviations provided by C. Gordon (personal communication 18 
July, 2003). Component scores have been calculated with coefficients from ABS 
(1997, p. 31). 
* p < .05 compared with healthy control group. 
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PSE-Tesl 
Table 5 presents the PSE-Test results for the three study groups. The 
composite score (CS) is the summation of the sub-test scores, the calculation of 
which was previously described. The sub-test scores have been transformed to T-
scores by using the norms relevant to each participant from the Manual (Schomerus, 
et al., 1999). 
The Levene test for homogeneity of variance was not significant (p >.05) so a 
one-way univariate analysis of variance (ANOVA) was performed on the dependent 
variable CS. The independent variable was group (defined by HCV status). ANOV A 
was significan~ F(2, 29) ~ 4.63,p ~ .018. Tukey HSD post hoc comparisons showed 
a significant difference between the mild HCV and moderate HCV groups (p = 
.013). 
However, ANOVA also showed a significant difference on the DV, IQ 
Equivalent, F(2, 29) ~ 9.0, p~ .00 I. Tukey post hoc comparisons showed significant 
differences between the healthy control and the modemte HCV group(p = .001) and 
also between the mildHCV group and the moderate HCV group (p ~ .018). A 
significant Pearson correlation (r = .616) was found between the IQ Equivalent and 
the CS, confinning that the IQ Equivalent was an important covariate. An ANCOVA 
with the IQ Equivalent as a covariate failed to find a significant difference between 
the groups on the dependent variable, CS, F(2,28) ~ 3.32,p ~ .051. 
---------------
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Table 5 
PSE-Syndrome-Test Age Adjusted Mean T-scoresa Study Groups 
Female/Male Ratio 
IQ Equivalent 
Sub Test'i 
Digit Symbol 
NCTA (s) 
NCTB(s) 
Serial Dotting (s) 
Line Tracing Time (s) 
Line Tracing Errors 
Composite Score (CS) 
Healthy 
Controls 
(n ~ 13) 
5:8 
116.00 
54.45 
58.29 
58.77 
60.53 
47.05 
66.14 
2.46 
Mild 
HCV 
(n ~II) 
6:5 
I! 1.55 
60.86 
62.31 
60.02 
66.00 
46.40 
67.16 
3.55 
Moderate 
HCV 
(n ~ 8) 
2:6 
100.38 
43.88 
59.55 
45.83 
54.40 
50.06 
65.89 
0.75 
Note. aT-scores (M =50, SD = 10) transformations were calculated with age means 
and SDs from the Manual (Schomerus eta!., 1999) 
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Relationship Between PSE~Test and SF-36 Results 
As indicated in Table 6 there were no significant Pearson correlations between 
the CS and the PCS, or the MCS. 
Table 6 
Correlations Between !Q, CS, PCS, and MCS 
Variable IQ cs PCS MCS 
IQ 1.00 .62• .27 .29 
cs .62• 1.00 .20 .21 
PCS .27 .20 1.00 .29 
MCS .29 .21 .29 1.00 
Note. • significantly correlated p < .01 
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Discussion 
The first aim of this study was to assess the three test instruments in a West 
Australian setting and in the han~s of this researcher. In line with its excellent 
reputation, the SF-36 was well accepted by both the university students in the control 
group, and the HCV -positive patients. As recommended in the Manual the SF-36 
was the first test administered and it provided a relaxing and easy start to the testing 
Hessions. The scoring of the mainly Likert-type questionnaire has some intricacies 
.:md the Manual recommends the use of computerised scoring systems and in 
particular, the service provided by the license holder (QualityMetric IncorJX)rated). 
Unfortunately, this service is not available for use with Australian nonns. Because 
no local scoring system could be accessed the researcher designed a simple Excel 
system which was thoroughly tested with a data set made available by 
QualityMetric. In a series of personal communications (M. Kosinski, September, 
2003) the question of which nonns to use was canvassed The decision was made to 
use the Australian nonns and scoring algorithms. However, it is worth considering 
using US nonns and algorithms for future Western Australian SF-36 studies in order 
to provide the opportunity to use the very comprehensive norms and wide range of 
study data in the two SF-36 Manuals. In this context it is noted that the major 
nonnative study in Australia dates back to 1995 and many major instruments, such 
as the WAIS-III, are used in Australia with US nonns. Also, in the case of this 
current study there were only small differences between the results calculated with 
Australian algorithms and the results calculated with US algorithms. For example, 
taking the control group's results and using Australian norm based scoring the PCS 
was 55.53 (US based~ 57.14) and MCS was 53.89 (US based~ 54.32). The SF-36 
Hepatitis C and Quality of Life 43 
results for the control group in this current study have been very much in line with 
expectations as discussed in the Results. 
The PSE-Test has not been used in Australia, but it was recommended by a 
well-credentialed consensus group at the 11th World Congresses of 
Gastroenterology, 1998 (Ferenci et al., 2002). The Licence Holder, Swets Test 
Services, Frankfurt. gave permission for the test forms to be translated into English 
and copied, pending the publication of an English version of the Test English test 
instructions were provided by one of the test authors (Professor Karin Weissenborn, 
personal communication, August 4, 2002). The Test was well accepted by the 
participants who without exception, worked very hard to do we11 in all the sub-tests. 
As discussed in the Results an inspection of Table 3 shows that the Test perfonned 
as expected with the exception of Line Tracing Errors. There seems to be little doubt 
that there is something different between this Western Australian administration of 
the Line Tracing Test and the Gennan administrations. A participant variable could 
explain part of this fairly unusual result, and all of the participants were 
conscientious to a fau)t, however, it is suspected that there is some difference 
between the English and Gennan versions of the instructions. A small experiment 
was conducted with one participant using firstly the English instructions as provided, 
and then repeating the test emphasising more clearly the need for speed as well as 
the need to make few errors. The participant did the test in 71 seconds with no errors 
in the first administration, and in the second trial the time taken was 30 seconds with 
a very low five errors. There would have been a practice effect, but not of the 
magnitude of the observed difference. This matter is currently under discussion with 
the senior test author, Professor Weissenborn (personal communications, October 
2003). From the viewpoint of the study, the Line Tracing Error results are almost 
Hepatitis C and Quality of Life 44 
identical across the three groups so they should not have affected any merua 
comparisons. However, it is necessary to resolve this matter to achieve internatim;al 
c~mparability. 
The control group performed as expected on the NART with an average lQ 
equivalent of 116. The Beardsall and Brayne ( 1990) approach of administering half 
of the test first and only proceeding to the second half if good results were achieved 
in the first half, was most appropriate and allowed the test sessions to finish on a 
pleasing note for all participants. 
OveraU the tests performed very well. Were they the right choice? The SF-36 
is certainly simple, cheap, reliable and valid and the instrument of choice in most 
recent studies of HCV affected HRQOL. It is hard to find fault with this HRQOL 
instrument although it has been noted that Forton, Thomas, and Taylor-Robinson 
(2003) have expressed concern that there is no cognitive function scale. This may be 
a valid point, but if changes have to be made it would be preferable to add an 
additional scale rather than seek a new test. 
The PSE-Test is simple and cheap to administer and it has been endorsed by a 
group of leading gastroenterologists after 30 years of experimentation with different 
measures of mHE. Therefore, this test must be the first choice for research into 
mHE. It is however, debateable whether the PSE-Test was ideal for use with the 
healthy control group and the group with mild chronic HCV. Forton, Thomas et at. 
(2002) suggested tbat HCV encephalopathy (HCVE) is qualitatively different from 
mHE. Consequently, they have not used the PSE-Test but have reHed on the results 
from the CDR Battery. It is relevant to note that COrdoba et al. (2003) have used 
neither the CDR Battery nor the PSE-Test, but have put together yet another battery. 
Convincing as their study is, there may have been merit in using a tailor-made 
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cognitive battery for at least one of the experimental groups. If it had been possible it 
would have been of interest ifCOrdoi>a et al. had used the CDR Battery, the PSE-
Test and, if considered necessary, additional tests. In the current study a tailor-made 
test for mHE was used. The PSE-Test does include well-established tests for general 
cognitive dysfunction, but if the resources had been available it would have been of 
interest to use the CDR Battery for all groups. 
The second goal of this study was to consider the appropriateness of the 
design. Difficulties have become obvious. Firstly, it is clear that the samples for each 
group were small and there was no chance of them being at all representative of the 
populations being studied. This is inevitable with all HCV studies because 
approximately one third of those with HCV have not yet been diagnosed. However, 
this current study also emphasised the recruitment of volunteers. The control group 
was recruited from a pool of university students on a volunteer register and they only 
participated if it was convenient. As it happened, nearly all of those approached 
agreed to testing and it is fair to say that a reasonable sample of the more mature 
university students on the School of Psychology Participant Research Register was 
obtained. Nevertheless, it could be expected that people who volunteer to be 
included on such a register are more confident and have better time management 
than students who do not volunteer. 
With the patients who volunteered from the private medical practice, the 
volunteer effect was almost certainly magnified. The relatively small proportion of 
patients who were prepared to volunteer can be seen as a confident and competent 
sub-set of those people attending a particular private practice. But this practice was 
also found in an upper middle class environment and the consultant is a leading 
Western Australian gastroenterologist. One could expect that his patients are used to 
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finding the best solution to their problems and this executive quality is one of those 
that the PSE-Test is aiming to measure. 
It has to be emphasised that volunteer patients from private consulting rooms 
are almost certainly not representative of people with HCV. But this also means that 
people who attend o lltpatient clinics at public hospitals are not representative of 
diagnosed patients either, and it is these people who are nonnally recruited for HCV 
studies. 
Another problem with the present study was the impossibility of controlling for 
the very large range of patient variables. Owing to the private nature of the practice, 
important variables such as education, occupation, mode of infection, and marital 
status were not sought. Some of the patients however, did volunteer personal details 
and it was obvious that there was considerable variability on these factors. In 
addition, some of the participants mentioned comorbid conditions. All the patients 
were screened for such conditions and were excluded from the study if the medical 
consultant believed these comorbidities affected cognitive function. However, other 
comorbidities might have had an effect on SF-36 scores. 
The question of comorbid conditions in HCV research raises considerable 
concern. The previously cited study by Fontana et al. (2002) illustrated the problem. 
Of220 HCV-positive people in the study, from 406 patients invited, 157 (71%) had 
active psychiatric or physical conditions requiring treatment or monitoring; 33% had 
depression, 9% anxiety, 40% musculoskeletal problems, 20% cardiovascular, 19% 
gastroenterological, 17% endocrine, I 0% pulmonary, and 13% 'other'. This is not to 
say that these problems are caused by HCV and Speed (200 I) suggested that there 
are only three accepted non-hepatic manifestations of HCV out of the more than 40 
non-liver related diseases that have been linked to HCV. However, whether the 
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comorbidities are manifestations of HCV or not, the fact remains that these 
comorbidities are important variables, indeed, so important that Hussain et al. (2001) 
found the presence of comorbidities to be the most important predictor ofHRQOL in 
CHC patients. 
The need for appropriate exclusions, the need to maintain a particularly high 
standard of privacy and the need for large numbers of participants makes it difficult 
to see how the current exploratory study design could be extended to full-scale 
research in the private practice environment. However, longitudinal, repeated 
mear.ures research with its better control over participant variables, could be practical 
and meaningful In fact, there is currently an excellent opportunity t.J test, by a 
repeated measures study, the Forton, Thomas et aJ. (2002) contention that HCV per 
se causes cognitive dysfunction. At present there is a large backJog of patients 
waiting for government approval for treatment with ribavirin and pegylated 
interferon. If such people were tested before treatment and after a sustained viral 
response (SVR; negative to HCV-RNA six months after treatment completion) then 
convincing evidence should be obtained about cognitive performance in people with 
and without the HCV virus. The test battery would include at least the SF-36 and the 
PSE-Test. The CDR Battery would also be included if it could be practically 
administered. The addition of neurophysiological measures would complete the 
picture, but perhaps exceed any practical budget. Such a project may also provide 
information on minimal hepatic encephalopathy in those with advanced liver disease. 
This could be feasible because it is well established that fibrosis at Knodell stages 1 
to 5 is reversible and there is mounting evidence that cirrhosis is as well. However, 
there is a problem because it is still not clear how quickly liver damage is reversed 
after an HCV cure (Friedman, 2003). 
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Consideration will now be given to the first hypothesis that looked towards a 
decline in HRQOL at the time of an HCV-positive diagnosis. The current research 
showed a statistically significant HRQOL reduction in the mild HCV group 
compared to the healthy controls. This supports the hypothesis and adds to the 
growing and close to compeiiing consensus built by the work of Bonkovosky and 
Woolley (1999), Cordoba et al. (2003), Doone aod Qoayle (2001), Foster et al. 
(1998), Miller et al. (2001), aod Rodger et al. (1999). 
What happens after many years is not so clear. It is noted that the very smaii 
moderate HCV group in the current study had a directional improvement in HRQOL 
compared to those with less liver damage. This is at variance with the study by 
Foster et al. (1998) who found a non-significant reduction ofHRQOL in people with 
moderate HCV compared to those with mild HCV. Part of this conflicting evidence 
could be explained by the preponderance of males (75%) in the moderate HCV study 
group, because HRQOL is higher in males than females in both AustraJian and US 
norms (ABS, 1997, Ware & Kosinski, 2001 ). Another possible explanation cou1d be 
that the moderate HCV group may have learned to accommodate their HCV-positive 
status, or they could have enjoyed a pali.icularly high level of support in a successful 
transitional process (Glacken et aJ., 2001). It could be that as HCV progresses there 
are two processes at play: firstly, a reduction of psychosocial impacts as could be the 
case with the moderate HCV group; and secondly, an increase of physical symptoms 
arising from an increasingly damaged liver. The study did not provide strong support 
for the hypothesis that HRQOL remains constant after the reduction associated with 
an HCV diagnosis until ChildPugh B/C cirrhosis, but nor did it argue against the 
hypothesis which has received good support from most authors and most 
convincingly from the recent work of COrdoba et al. (2003 ). 
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The present study did not aim to research the relationship between HRQOL 
and end-stage HCV, but to complete the HRQOL picture it seems reasonable to 
accept the Hepatitis C Virus Projections Working Groups (2002) estimate of a 
reduction in the quality of life of around 68% when jaundice, ascites, gastrointestinal 
bleeding and psychomotor difficulties are being experienced. 
The third hypofuesis was that cognitive function deteriorates in people with 
mild HCV. The study gave no support to this hypothesis. In fact there was a 
directional improvement in PSE-Test results in the group with mild HCV compared 
to the healthy controls. This unexpected result contributed to a large difference in 
PSE-Test results between those with mild and moderate HCV. However, the 
difference reduced to below significance when an 11.15 percentage point difference 
in pre-morbid intelligence was factored into the analysis as a covariate. 
Consequently, the study did not support the fourth hypothesis which looked for a 
cognitive decline in people with HCV and Child-Pugh A cirrhosis. The nwnbers in 
the modemte HCV group and the characteristics of the participants make the findings 
concerning this fourth hypothesis unhelpful. 
AJthough there were no reportable differences between the groups on PSE-Test 
scores, there were some important points arising from the study. Firstly, it is 
interesting to note that only two of the 19 HCV -positive participants scored below 
their relevant age and sex nonn means on the NCTA, a test of attention and 
motivation among other things. The average was more than one standard deviation 
better than the age adjusted mean. These results confirm the previous suggestion that 
the HCV-positive patients were a special sub-group of a special medical practice. 
The second point arising from the cognitive testing was that the people with 
mild HCV performed better, but not significantly better than the university students. 
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The group means for those with mild HCV would have been even better had the 
resuJts of one participant (NART score = 96) been deleted. The out-perfonnance of 
this group is partly explained by the special group effect, but the filet is that the 
group did exceptionally well and it is hard to believe that they coald have done better 
before they were infected with HCV. It is considered that this adds to the evidence of 
Forton, Thomas et al. (2002) and Cordoba et al. (2003) that HCV does not affect 
perfor' ':.lnce on tests like the PSE-Test. There- ·mains the possibility ofHCV-
rela' 'gnitive abnonnalities which are only detectable by neurophysiological 
techmques and/or computer tests such as the CDR Battery. But the case has not yet 
been made that results on these tests have a strong relationship to every day living. 
The third matter of cognitive note arising from this exploratory study is that 
only one of the HCV-positive patients had a pathological PSE-Test score result of 
worse than minus 4. However, that person, whose score was minus 5, had a NART 
score of 81 so pre-morbid intelligence played a major role in the PSE-Test results. In 
fact, the participant went about the tests in a rather organised, although slow manner. 
The participant achieved two scores within the nonnal range which can be seen as 
quite an achievement. 
This present and other research has found no evidence of cognitive dysfunction 
in those with mild or moderate HCV. To consider people with compensated cirrhosis 
it had been hoped to recrui.t a reasonable number of Child-Pugh A cirrhotics. As this 
was not possible, little comment can be made on the effects of compensated cirrhosis 
on cognitive function. On the basis of the full-scale study by Cordoba et al. (2003), it 
would seem that cognitive dysfunction is not evident in compensated cirrhotics and 
does not become important until end-stage liver disease. 
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The fifth hypothesis was that reduced HR.QOL is associated with cognitive 
dysfunction. The hypothesis was based particularly on the work by Groeneweg et al. 
(1998) who found a strong relationship between cognitive function and quaJity of 
life. Their methodology was to diagnose cirrhotics with mHE and then compare the 
quality of life of cirrhotics with and without mHE. This opportunity was not 
available in the current study as no one had mHE. Across all participants there were 
small positive correlations between the PSE-Test composite score (CS) and the SF~ 
36 physical and mental component summary scores (PCS and MCS). These 
correlations were not significant and therefore the fifth hypothesis was not 
supported. It would be of interest to reconsider this area of research given a sample 
with greater variability in PSE-Test results. Such research could be quite difficult 
because cognitive dysfunction seems to b...~ome significant only in people with 
advanced liver disease (C6rdoba et ai.. 2003). Research undertaken with these people 
would pose the problem of controlling for major physical symptoms. 
In summary, and in relation to the research questions, the evidence from this 
and other studies, suggests that: a) t.he SF-36, PSE-Test and NART are all useful 
instruments and suitable for use in a variety of environments; b) cross-sectional 
designs are problematic in private medical practice settings; c) HRQOL in people 
with HCV declines at the time of diagnosis and then stays fairly constant until the 
serious consequences of advanced liver disease become apparent; d) cognitive 
function is not greatly affected by HCV until the onset of advanced liver disease; and 
e) a direct relationship between cognitive declines and HRQOL changes, has yet to 
be satisfactorily demonstrated. 
From a practical point of view it is important for people infected with HCV to 
be aware that there is no solid evidence that the hepatitis C virus will cause cognitive 
Hepatitis C and Quality of Life 52 
dysfunction relevant to everyday living. In addition, the chances are very small of 
HCV progressing to advanced liver disease and possible cognitive complications. 
What is even more important is the relevance of this and similar research tQ anti-viral 
treatment. This has progressively become more effective since the early 1990s and is 
likely to continue to improve (Foster, 2002). The offer of treatment, outside of 
clinical trials, has up until now been based on liver biopsy proof of a reasonable 
degree of liver damage. The thinking has been that there is little point in subjecting 
people to unpleasant treatment that may not be successful, unless there are clear 
indications that the untreated infection will progress to the serious physical 
consequences of advanced cirrhosis. As observed by Foster, this approach is no 
longer appropriate, because treabnent with ribavirin and pegylated interferon now 
gives good odds of a cure and the most important issue for the majority of people 
with HCV infection is the HRQOL decrement resulting from diagnosis. In current 
health care settings the cost effectiveness of any medical treatment should be 
justified on the grounds of quality of life years gained (Y ounossi & Guyatt, 1998). 
Therefore, the offer of anti viral treatment should be targeted at those people with the 
greatest current HRQOL decrements as well as those people with an expectation of 
future lost quality oflife. 
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Appendix A 
Modified Staging: Fibrosis and Cirrhosis (Knodell) 
Change 
No fibrosis 
Fibrosis expansion of some portal areas, with or without 
short fibrous septa 
Fibrous expansion of most portal areas, with or without 
short fibrous septa 
Fibrous expansion of most portal areas with occasional 
portal to portal (P-P) bridging 
Fibrous expansion of portal areas with marked bridging 
(P-P) as well as portal to central (P-C) 
Marked bridging (P-P and /or P-C) with occasional nodules 
(incomplete cirrhosis) 
Cirrhosis, probable or definite 
Note. Ishak et al. (1995) 
Score 
0 
2 
3 
4 
5 
6 
AppendixB 
Proposed Nomenclature of HE 
HE Type 
A 
B 
c 
Nomenclature 
Encephalopathy 
associated with acute 
iiveo faiiure 
Encephalopathy 
associated with penal-
systemic bypass and no 
.,., ·iMie hepawcellular 
.H. ,..,~ft 
Encephalopathy 
associateti with 
cirrhosis and portal 
hypertension/or portal-
systemic shunts 
Note. Ferenci et al. (2002). 
*Without recognized precipitating factors 
Subcategory 
Episodic HE 
Persistent HE 
Minimal. HE 
Subdivisions 
Precipitated 
Spontaneous* 
Recurrent 
Mild 
Severe 
Treatment· 
dependent 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Appendix C 
Semiquantitative Grading of Mental State 
(West Haven Criteria) 
Trivial: lack of awareness 
Ehphoria or anxiety 
Shortened attention span 
Impaired performance of addition 
Lethargy or apathy 
Minimal disorientation for time or place 
Subtle personality change 
Inappropriate behavior 
Impaired performance of subtraction 
Somnolence to sen.istupor, but responsive to verbal stimuli 
Confusion 
Gross disorientation 
Coma (unresponsive to verbal or noxious stimuli) 
Note. Ferenci et.al. (2002). 
:: 
Appeudix D 
Precis - Review of t 7 HE Patients 
(Summerskill, Davidson, Sherlock, & Steiner, 1956) 
D I of2 
The neuropsychiatric complications of these patients had lasted six months to 
six years. Al1 patients showed sleep disorders, with excessive sleep being an early 
feature and then an inversion of sleep patterns in some patients. In early to middle 
stages of the syndrome there was a reduction in spontaneous movements, apathy and 
general slown¢ss. A.s dysfunction increased the patients reacted only to intense 
stimuli and then coma set in. This first resembled normal sleep but deteriorated to 
foetal attitudes, rigidity and irregular breathing. 
All patients showed various det..Jfees of personality change and six of the 
patients showed intensification of previous personality trends. Frontal lobe 
involvement was suggested by the authors with patients being sociable, jocular, 
unselfconscious and with little drive or initiative when symptoms were at their 
mildest, but when symptoms were more severe there were cases of incontinence, 
violence, extreme extroversion, paranoia, childishness, irritability and even of 
flirting by a Presbyterian minister. 
Although mood fluctuated it remained constant in the majority for several days 
or weeks at a time. Seven of the patients had phases of both depression and euplwria, 
five showed changes in the direction of euphoria only, four showed changes in the 
direction of depression only, and one patient had a stable mood that only changed at 
the height of stupor when she became enraged. 
When patients were fully conscious and accessible, their memory for remote 
events was unimpaired but short-tenn memory as tested by digit span and lhrce 
D2 of2 
minute retention methods became progressively impaired. Knowledge of time was 
disturbed before that of place or identity and spatial orientation was also affected 
early. Patients would get lost in their own home and be unable to find doors and light 
switches. Visual agnosia was shown in some patients when semi-conscious, with 
some urinating in drawers, baths or shoes and one shaving with his toothbrush. 
Speech was slow and slurred and some had difficulties with trembling lips and the 
biting of tongues. The presence of visual problems, tremors and poor hand-eye 
coordination contributed to writing difficulties. 
Pyramidal and extrapyramidal elements were evident. The 'flapping' tremor of 
asterixis was typical, agt,'l'avated by fatigue, anxiety or excitement. Intentional 
movement was disrupted in the more severely affected patients. The unusual 
combination of muscle rigidity, ankle clonus and flexor plantar was frequently 
observed. All patients were sensitive to nitrogenous substances and a high {lfPtfin 
diet or the administration of ammonium chloride resulted in an increase in 
neuropsychiatric disturbances. Splenomegaly was found in all patients, as was an 
extensive portal-systemic collateral circulation. 
Appendix E 
Invitation to Participate in S!udy 
Letter typed on Professor Reed's Letterhead 
Dear 
Invitation to Participate in Hepatitis C Research 
An Honours student from Edith Cowan University. Mr John Caithness, is currently 
investigating possible cognitive effects associated with hepatitis C infection. The 
Hollywood Private Hospital Research Ethics Committee has given approval for this 
study as have the Ethics Committee of the Faculty of Community Services, 
Education and Social Sciences of Edith Cowan University. 
The purpose of this study is to observe any differences in COblllitive function between 
groups of patients with hepatitis C with various stages of liver damage. by 
administering specific tests that measure quality of life. fine motor skills. 
concentration and reading ability. It is expected that these tests will take about 60 
minutes of your time. This study may assist in the consideration of appropriate 
treatment and care of patients with varying stages of chronic hepatitis C and 
therefore has my support. 
If you agree to participate in the study Mr Caithness will contact you by telephone. 
He will arrange a convenient time and place to administer the tests and send you a 
letter confirming details and providing more information. Prior to the administration 
of the tests you will be asked to consider this information more fully, given the 
opportunity to ask questions, and then asked to complete a Patient Consent Form. To 
ensure complete confidentiality. you will be allocated a code number that will be 
used on the test fonns and research data. The master list showing your name and 
allocated code will be maintained in my office under lock and key. Should you wish 
to find out your results on the tests, which you are very welcome to do. I will discuss 
them with you. Names will not be reported in the study and should the results be 
published, participants will not be identifiable. 
Whether you participate or not is entirely voluntary. If you do decide to participate 
then if at any time you wish to withdraw from this study. you arc free to do so 
without prejudice or affecting your current or future medical care. Questions 
concerning this study can be addressed to myself, or John Caithness. telephone (08) 
9284 7834.1fyou have any concerns about this study please do not hesitate to 
contact Dr Teny Bayliss, Chairperson. Research Ethics Committee Hollywood 
Private Hospital, Monash Avenue, Nedlands WA 6009, telephone (08) 9346 6249. 
Thank you for considering the contents of this letter. My secretary, 
Mrs Sheryle Craven will contact you in a few days to sec if you are willing to 
participate in the study. 
Yours sincerely 
Professor W. D. Reed 
Appendix F 
Appointment Confirmation Letter 
Typed on Edith Cowan University Letterhead 
July 2003 
Name 
Address 
Suburb, W A PC 
Dear Name 
Hepatitis C Study 
We spoke together this afternoon and I am very appreciative of your agreement to 
participate in our study. Jam sure you will find it interesting. Just confirming our 
arrangements we organised to meet at your place, at the above address, at 9.30am 
Wednesday 9 July. 
As an Honours student from the School ofPsycholo~:,ry at ECU I am currently 
conducting research into the possible cognitive effects associated with hepatitis C 
infection. Details of the study are in the attached Participant Information Sheet. 
When we meet I will ask you to consider the Information Sheet in detail. You will be 
free to ask me any questions you like and you will then be asked to complete a 
Consent Form. If you arc happ~' with this, the tests detailed in the Information Sheet 
will be administered. 
Participation is entirely voluntary and if at any time you wish to withdraw from this 
study, you are free to do so without prejudice or any negative consequences. 
Please let me know if you have any questions that arise from this study. My phone 
nwnber is (08) 9284 7834. If you have any difficulty contacting me feel free to ~peak. 
to my Supervisor, Dr Elizabeth Kaczmarek on (08) 6304 5193. -~ 
Thank you again. 
Yours sincerely 
Student Researcher 
(John Caiti;ness) 
AppendixG 
Participant Information Sheet 
Study Title: Cognitive Changes in Individuals with Chronic Hepatitis C 
Investigator: John Caithness 
Approvals: The Hollywood Private Hospital Research Ethics Committee has given 
approval for this study, as has the Research Ethics Committee at Edith Cowan 
University. 
Purpose: To assess any differences in cognitive function between groups of patients 
with hepatitis C and various degrees of liver damage. 
Procedures: Three tests, taking less than 60 minutes in total, wilJ be administered, 
individually and in private: 
I. a paper and pencil test which measures visual orientation, 
concentration and hand/eye motor speed and accuracy. 
2. questionnaire with 36 items about your state of health. 
3. a reading ability test requiring the pronunciation of25 words. 
Expected Benefits: While this study is exploratory and small in scale it is expected 
that it wil1 contribute to the existing body of research on the care of patients with 
varying stages of chronic hepatitis C. There are no expected personal benefits from 
participating in this study. 
Confidentiality: To ensure confidentiality, you will be allocated a code nwnber that 
will be used on the test fonns and research data. The master list of names and codes 
for patients at Hollywood Private Hospital will be held under lock and key by 
Professor Reed. For students from Edith Cowan University the master list will be 
held under lock and key by Dr Elizabeth Kaczmarek. Names will not be reported in 
the study and should the results be published, participants will not be identifiable. 
Compensation: Your participation will be greatly appreciated, but no monetary 
compensation will be t'rovided. It is noted that your rights at Australian law do not 
change upon signing the consent fonn for this study. 
Withdrawal: Participation is entirely voluntary and if at any time you wish to 
withdraw from this study, you are free to do so without prejudice or any negative 
wnsequences, and in the case of patients from Hollywood Private Hospital there will 
be no affect on your current or future medical care. 
Concerns: If you have any concerns about this study please do not hesitate to 
contact Edith Cowan University's Professor Alison Garton on (08) 6304 5110, or Dr 
Terry Bayliss, Chairperson, Research Ethics Committee Hollywood Private Hospital, 
Monash Avenue, Nedlands WA 6009, telephone (08) 9346 6249 
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AppendixH 
Edith Cowan University Participants Consent Fonn 
Typed on Edith Cowan University, School of Psychology, Letterhead 
Consent to Participate in Psychological Study 
Please read the following statements. Tick (..J) the boxes {fyou agree. The testing 
procedure. will only start if you are happy Jo lick all of the bfJ.XeS.. 
0 I have read the information sheet. 
D I was given adequate opportunity to ask questions. 
0 The questions I asked were answered to my satisfaction. 
0 I understand the content of the infonnation sheet. 
D I understand the nature of the study. 
0 I understand that I am not obliged to participate in the study. 
0 I understand that I may refuse to answer questions, refuse to start an.y 
tests, or may at any time withdraw from this study. 
0 I realise that there will be no negative consequences should I decide 
not to participate or stop participating. 
0 I understand that if this research is published then the participants will 
not be identified. I consent to such publication. 
0 I confinn that I voluntarily chose to complete this questionnaire. 
If you have ticked each ofJhese boxes we can proceed to adminisJer the three tests. 
Signed at (place), ____________ _ 
On the -=o------- day of ----------
2003 
Signature of participant 
Name (Please print) 
AppendixH 
BOLL YWOOD PRIVATE HOSPITAL 
PATIENT CONSENT FORM 
TITLE: Cognitive Changes in Individuals with Chronic Hepatitis C 
INVESTIGATOR: John Caithness 
To be completed by the Participant of the study: 
1. Have you read the infomtation sheet about this study? Yes 0 NoD 
2. Have you had an opportunity to ask questions and discuss this study? Yes D No D 
3. Have you received satisfactory answers to aU your questions? 
4. Have you received enough information about this study? 
5. Which Doctor (or other researcher) has spoken to you 
about this study? 
6. Do you understand that you are free to withdraw from this 
study at any time without giving a reason and without 
affecting your current or future medical care? 
7. Do you agree to take part in this study? 
Yes 0 No 0 
Yes 0 No 0 
Yes 0 No 0 
Yes D NoD 
8. Have you received a copy of the infonnation sheet and consent fonn? Yes 0 No 0 
YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM 
Participant's Name Participant's Signature 
Person Obtaining Consent Signature 
Witness Name Signature 
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Date 
Date 
Date 
General Linear Model Appendix I ll ofll 
Between-Subjects Factors Statistical Analvsis of Data 
V:>lue Label N 
GROUP 1 moderate 8 
2 minimal 11 
3 health 13 
Multtvarlate Test!f 
Effect Value F HYI!Q!hesls df Error df Si. 
Intercept Pillal's Trace .986 997.40811 2.000 28.000 .000 
Wilks' Lambda .014 997.40811 2.000 28.000 .000 
Hotelling's Trace 71.243 997.40811 2.000 28.000 .000 
Rev's largest Root 71.243 997.40811 2.000 28.000 .000 
GROUP Pillal's Trace .318 2.737 4.000 58.000 .037 
Wilks' lambda 
.665 2.91911 4.000 56.000 .029 
Hotelling's Trace .457 3.085 4.000 54.000 .023 
Rov'r. Lamest Root .449 6.518b 2.000 29.000 .005 
a. Exact statistiC 
b. The statistic Is an upper bou11d on F that yields a lower bound on the significance level. 
c. Design: lntercept+GROUP 
Tests of Between-Subjects Effects 
I I 
a. R Squared= .209 (Adjusted A Squared= .155) 
b. A Squared= .195 (Adjusted R Squared= .139) 
Post Hoc Tests 
GROUP 
Page 1 
Based on observed means. 
Multiple Comparisons 
,1.' 
Mean 
Difference 
12ofll 
Page2 
NPar Tests I3ofll 
Kruskai-Wallis Test 
Ranks 
GROUP N Mean Rank 
PCS moderate 8 14.38 
minimal 11 12.18 
healthy 13 21.46 
.,.otal 32 
MCS moderate 8 13,00 
minimal 11 12.64 
healthy 13 21.92 
Total 32 
Test StaUsticsa.b 
PCS MCS 
Chi-Square 6.378 7.324 
df 2 2 
AS""'"· Sin. .041 .026 
a. Kruskal Wallis Test 
b. Grouping Variable: GROUP 
Page 1 
Oneway I 4 of I I 
Test of Homogeneity of Variances 
Levene 
Statistic df1 df2 Sia. 
PF 3.077 2 29 .061 
RP 17.939 2 29 .000 
BP 3.192 2 29 .. 056 
GH 5.375 2 29 .010 
VT 5.702 2 29 .008 
SF 6.148 2 29 .006 
RE 5.908 2 29 .007 
MH 4.769 2 29 ,016 
PCS 2.650 2 29 ,088 
MCS 10.971 2 29 .000 
ANOVA 
_:\!mol ares dl Mean Square F Slg. 
PF Between Groups 12B.4B4 2 64.242 1.326 .281 
Within Groups 1404.499 29 48.431 
Total 1532.983 31 
RP Between Groups 554.646 2 277.323 3.565 .041 
Within Groups 2255.835 29 77.787 
Total 2810.481 31 
BP Between Groups 546.128 2 273.064 4.117 .027 
Within Groups 1923.376 29 66.323 
Total 2469.505 31 
GH Between Groups 1758.153 2 879.076 9.402 .001 
Within Groups 2711.414 29 93.497 
Total 4468.567 31 
VT Between Groups 707.150 2 353.575 4.546 .019 
Within Groups 2255.372 29 77.771 
Total 2962.521 31 
SF Between Groups 435.225 2 217.613 2.774 .079 
Within Groups 2274.606 29 78.435 
Total 2709.831 31 
RE Between Groups 758.910 2 379.455 2.728 ,082 
Within Groups 4033.371 29 139.082 
Total 4792.282 31 
MH Between Groups 505.032 2 252.516 3.815 .034 
Within Groups 1919.331 29 66.184 
Total 2424.364 31 
PCS Between Groups 384.857 2 192.429 3.836 .033 
Within Groups 1454,600 29 50.159 
Total 1839.457 31 
MCS Between Groups 642.894 2 321.447 3.503 .043 
Within Groups 2661.076 29 91.761 
Total 3303.970 31 
Post Hoc Tests 
Page 1 
Multiple Comparisons 
4.5313 3.65954 
2.50434 
4.09775 
4.09TI5 
15ofll 
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Multiple Comparisons 
minimal 
Mean 
Difference 
16 of II 
3.97967 
4.63948 
4.63948 
3.78017 
3.78017 
Page 3 
Multiple Comparisons 17ofll 
Mean 
Oe~!ldent Variable II\ GROUP (J\ GROUP Diff~:~nce Std. Error s;g, 
MCS TukeyHSD moderate minimal 4.5962 4.45108 .563 
hea•hy -5.7422 4.30450 .aaa 
minimal moderate 
-4.5962 4.45108 .563 
healthy 
-10.3385" 3.92435 .035 
healthy moderate 5,7422 4.30450 .388 
minimal 10.3385" 3.92435 .035 
Tamhane moderate minimal 4,5962 4.77094 .727 
healthy 
-5.7422 2.67136 .140 
minimal moderate 
-4.5962 4.77094 .727 
healthy 
-10.3385 4.55999 .119 
healthy moderate 5.7422 2.67136 .140 
minimal 10 3385 4.55999 119 
Page4 
Oneway 
ANOVA 
PHES 
Sum of 
Squares df Mean Square 
Between Groups 36.261 2 18.130 
Within Groups 113.458 29 3.912 
Total 149.719 31 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable: PHES 
Tukey HSD 
Homogeneous Subsets 
PHES 
Tukey HSD8 'b 
Subset for alpha-" .05 
GROUP N 1 2 
moderate 8 .7500 
healthy 13 2.4615 2.4615 
minimal 11 3.5455 
Sia. .141 .440 
Means for groups m homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 10.245. 
b. The group sizes are unequal. The harmonic mean of the 
group sizes Is used. Type I error levels are not guaranteed. 
I R of II 
F s;g. 
4.634 .018 
Page 1 
Oneway 
Test of Homogeneity of Variances 
NART 
l.evene 
Statistic dl1 
2.521 2 
NART 
Within Groups 
Post Hoc Tests 
Dependent Variable: NART 
Tukey HSD 
df2 Sio. 
29 .098 
ANOVA 
Multiple Comparisons 
•. The mean difference is &lgnific;mt at the .05 level. 
Homogeneous Subsets 
NART 
Tukey HS08 'b 
Subset for al ha .05 
GROUP N 1 2 
moderate 6 100.3750 
minimal 11 111.5455 
healthy 13 116.0000 
Sia. 1.000 .450 
Means for groups 10 homogeneous subsets are diSplayed. 
a. Uses Harmr.nic Mean Sampltl Size= 10.245. 
b. The group sizes are unequal. The harmonic mean of the 
group sizes Is used. Typt,j I error levels are not guaranteed. 
19of II 
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Correlations I 10 of II 
Correlations 
NART PCS MCS PHES 
NART Pearson Correlation 1 . 267 .267 .616 • 
Slg. (2-talled) .140 .111 .000 
N 32 32 32 32 
PCS Pearson Correlation .267 1 .285 .200 
Sig. (2-talled) .140 .113 .272 
N 32 32 32 32 
MCS Pearson Correlation .287 .285 1 .213 
Slg. (2-tailed) .111 .113 .243 
N 32 32 32 32 
PHES Pearson Correlation .616" .200 .213 1 
Sig. (2-talled) ~I .272 2~ N 32 32 
*".Correlation IS Significant at the 0.011eve1 (2-talled). 
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Univariate Analysis of Variance Ill of II 
Between-Subjects Factors 
Value Label N 
GROUP 1 moderate 8 
2 minimal 11 
3 heallhv 13 
Tests of Between-Subjects l;ffects 
Dependent Variable: PHES 
Sou"'" T~~~ISum of S uares dl Mean Sauare F Sia. 
!COrrected Model 74.69311 3 24.898 9.292 .000 
Intercept 27.768 1 27.768 10.363 .003 
NAAT 38.432 1 38.432 14.343 .001 
GROUP 17.796 2 6.898 3 -~·:21 .051 
Error 75.026 28 2.680 
' Total 335.000 32 
Corrected Total 149.719 31 
a. R Squared = .499 (Adjusted R Squared = .445) 
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